RXRX
Recursion Pharmaceuticals Inc ClasHenter pris…
Værdiansættelse (TTM)
Kursudvikling
Kun 79 handelsdage i databasen. Viser al tilgængelig historik.
Data-readiness
10 års prishistorik er idealet for høj confidence.
- Prishistorik
- 0,2 år
- Pris-dage
- 58
- Årsregnskaber
- 8
- Peers
- 0/0
- Valuation
- 3/6
- Fundamentals
- 7/8
- Datovindue
- 2026-02-17 til 2026-05-08
Blokkere
- Raw confidence is below the 0.95 high-confidence guardrail.
Mangler før højere confidence
- Mangler ca. 9,8 års prishistorik før ideal/full.
- Backfill mindst 1 års daglige priser før seriøs teknisk vurdering.
- Kør compute-multiples for manglende valuation metrics.
- Kør fetch-fundamentals-bulk/API fallback for manglende regnskabsmetrics.
Seneste assessment
RXRX vurderet 2026-06-10
Raw confidence is below the 0.95 high-confidence guardrail.
Stores exit-aware fields without issuing sell scores yet.
Current drawdown: Future exit logic can use drawdown from recent high.
Trend break: Future exit logic can use moving-average trend breaks.
Compares price paid with earnings, cash-generation proxies and sales.
P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.
Earnings yield: Earnings yield is the inverse P/E lens.
Checks trend, momentum and current damage from recent highs.
6M momentum: Positive medium-term momentum confirms sponsorship.
Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.
Checks whether the assessment has enough recent price, fundamental and valuation data.
Price history depth: More than one trading year gives the technical pillar enough context.
Latest price freshness: Latest live or EOD price should be recent.
Treats macro as context, not a standalone trading instruction.
VIX: Normal volatility is supportive; panic or complacency is less clean.
10Y-2Y curve: Positive yield curve lowers recession stress.
Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.
Revenue growth 3Y: Sustained top-line growth supports durable compounding.
Gross margin: High gross margin gives room for reinvestment and downturns.
Adds relative context when sector peers have comparable data.
Peer count: Peer context is only scored when comparable data exists.
P/E vs peers: P/E relative valuation needs both own multiple and peer median.
Insider activity
| Dato | Person | Rolle | Type | Antal | Værdi | Kilde |
|---|---|---|---|---|---|---|
| 18.6.2026 | Bumpus Namandje | — | ▼ SALG | -3.963 | -12.602 USD | sec |
| 17.6.2026 | Borgeson Blake | — | · ANDET | 88.424 | — | sec |
| 17.6.2026 | Bumpus Namandje | — | · ANDET | 88.424 | — | sec |
| 17.6.2026 | Li Dean Y | — | · ANDET | 88.424 | — | sec |
| 17.6.2026 | Dar Zavain | — | · ANDET | 88.424 | — | sec |
| 17.6.2026 | Sun Elaine D | — | · ANDET | 88.424 | — | sec |
| 17.6.2026 | Michor Franziska | — | · ANDET | 88.424 | — | sec |
| 17.6.2026 | HERSHBERG ROBERT | — | · ANDET | 88.424 | — | sec |
| 15.6.2026 | Taylor Ben R | Chief Financial Officer | · ANDET | -5.396 | -16.997 USD | sec |
| 5.6.2026 | Gibson Christopher | — | · ANDET | 40.000 | — | sec |
| 5.6.2026 | Gibson Christopher | — | ▼ SALG | -40.000 | -144.800 USD | sec |
| 5.6.2026 | Khan Najat | CEO and President | ▼ SALG | -23.588 | -84.459 USD | sec |
| 3.6.2026 | Bumpus Namandje | — | ▼ SALG | -4.386 | -15.526 USD | sec |
| 2.6.2026 | Borgeson Blake | — | ▼ SALG | -30.000 | -110.400 USD | sec |
| 22.5.2026 | Gibson Christopher | — | · ANDET | 40.000 | — | sec |
| 22.5.2026 | Gibson Christopher | — | ▼ SALG | -40.000 | -123.200 USD | sec |
Earnings
| Quarter | Date | EPS actual | EPS est | EPS surprise | Revenue surprise | |
|---|---|---|---|---|---|---|
| 2026Q1 | 30.4.2026 | -0,22 | -0,26 | +14.4% | +14.4% | Beat |
| 2025Q4 | 30.1.2026 | -0,21 | -0,32 | +33.3% | +33.3% | Beat |
| 2025Q3 | 30.10.2025 | -0,36 | -0,38 | +5.7% | +5.7% | Beat |
| 2025Q2 | 30.7.2025 | -0,41 | -0,35 | -16.0% | -16.0% | Miss |